Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing

被引:37
作者
Freedman, Mark S. [1 ,2 ]
Selchen, Daniel [6 ]
Prat, Alexandre [4 ,5 ]
Giacomini, Paul S. [3 ]
机构
[1] Univ Ottawa, Div Neurol, Dept Med, Ottawa, ON, Canada
[2] Ottawa Hosp Res Inst, Ottawa, ON, Canada
[3] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada
[4] Univ Montreal, CRCHUM, Fac Med, Montreal, PQ, Canada
[5] Univ Montreal, Dept Neurosci, Fac Med, Montreal, PQ, Canada
[6] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada
关键词
Multiple sclerosis; Long-term outcome; Relapsing remitting; PLACEBO-CONTROLLED TRIAL; BLOOD-BRAIN-BARRIER; GLATIRAMER ACETATE; INTERFERON BETA-1A; DISEASE-ACTIVITY; DOUBLE-BLIND; DIMETHYL FUMARATE; INTRAMUSCULAR INTERFERON; ALEMTUZUMAB TREATMENT; COMPARATIVE EFFICACY;
D O I
10.1017/cjn.2018.17
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Recent therapeutic advances in the management of multiple sclerosis (MS) have raised questions about the selection of appropriate patient candidates for various treatments and, if the plan is to move from one treatment to another, the appropriate sequencing of these therapies. The selected approach should provide optimal disease management without limiting future therapeutic options based on safety concerns, and recognize potential future treatments and the possibility of combination therapies. Additional challenges include incorporation of patient needs and preferences into the overall therapeutic approach, in order to ensure optimal outcomes in the short and long term. The objective of this manuscript is to provide an overview of what is currently known regarding the impact of various therapies for MS on future therapeutic choices (sequencing). In this context, we reviewed the available evidence in support of various treatments and, based on the presence of disease activity, suggested a scheme for switching or escalating therapy with the main focus on sequencing of therapeutic approaches.
引用
收藏
页码:489 / 503
页数:15
相关论文
共 142 条
  • [2] Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis
    Amato, M. P.
    Portaccio, E.
    Ghezzi, A.
    Hakiki, B.
    Zipoli, V.
    Martinelli, V.
    Moiola, L.
    Patti, F.
    La Mantia, L.
    Mancardi, G. L.
    Solaro, C.
    Tola, M. R.
    Pozzilli, C.
    De Giglio, L.
    Totaro, R.
    Lugaresi, A.
    Di Tommaso, V.
    Paolicelli, D.
    Marrosu, M. G.
    Comi, G.
    Pellegrini, F.
    Trojano, M.
    [J]. NEUROLOGY, 2010, 75 (20) : 1794 - 1802
  • [3] Antel J., 2014, CLIN EXP NEUROIMMUNO, V5, P49, DOI [10.1111/cen3.12079, DOI 10.1111/CEN3.12079]
  • [4] Awad Amer, 2009, Ther Adv Neurol Disord, V2, P50, DOI 10.1177/1756285609344375
  • [5] Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies
    Baroncini, Damiano
    Ghezzi, Angelo
    Annovazzi, Pietro O.
    Colombo, Bruno
    Martinelli, Vittorio
    Minonzio, Giorgio
    Moiola, Lucia
    Rodegher, Mariaemma
    Zaffaroni, Mauro
    Comi, Giancarlo
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (10) : 1315 - 1326
  • [6] An update on the evidence base for peginterferon 1a in the treatment of relapsing-remitting multiple sclerosis
    Bhargava, Pavan
    Newsome, Scott D.
    [J]. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2016, 9 (06) : 483 - 490
  • [7] Biogen Canada, TYSABRI PML Q UPD DE
  • [8] Biogen Canada Inc, 2016, PR ZINBRYTA PROD MON
  • [9] Biogen Idec Canada Inc, 2015, TECFIDERA PROD MON
  • [10] Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
    Bloomgren, Gary
    Richman, Sandra
    Hotermans, Christophe
    Subramanyam, Meena
    Goelz, Susan
    Natarajan, Amy
    Lee, Sophia
    Plavina, Tatiana
    Scanlon, James V.
    Sandrock, Alfred
    Bozic, Carmen
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (20) : 1870 - 1880